Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.71 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.71 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.71 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.71 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.71 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.71 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.71 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180215 | 0.92 | MAPT (0.84) | MAPTKDM4EPOLBATMCYP1A1 | |
| SCHEMBL1181195 | 0.87 | KDM4E (0.75) | MAPTKDM4EPOLBATMCYP1A1 | |
| SCHEMBL6693465 | 0.86 | MAPT (0.75) | MAPTKDM4EPOLBATMCYP1A1 | |
| SCHEMBL4279334 | 0.86 | KDM4E (0.75) | MAPTKDM4EPOLBATMCYP1A1 | |
| SCHEMBL28534175 | 0.86 | KDM4E (0.75) | MAPTKDM4EPOLBATMCYP1A1 | |
| SCHEMBL7532002 | 0.85 | KDM4E (0.74) | MAPTKDM4EPOLBATMCYP1A1 | |
| SCHEMBL13394699 | 0.84 | MAPT (0.73) | MAPTKDM4EPOLBATMCYP1A1 | |
| SCHEMBL13458065 | 0.84 | MAPT (0.73) | MAPTKDM4EPOLBATMCYP1A1 | |
| SCHEMBL14157031 | 0.84 | KDM4E (0.73) | MAPTKDM4EPOLBATMCYP1A1 | |
| SCHEMBL26134505 | 0.84 | KDM4E (0.72) | MAPTKDM4EPOLBATMCYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222160-B1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-8426587-B2 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD. (AU) | 2013-04-23 | — | — | US | disclosed |
| CN-101917845-A | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD | 2010-12-15 | — | — | CN | disclosed |
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (AU) | 2010-11-25 | — | — | US | disclosed |
| EP-2222160-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | Pharmaxis Ltd. (AU) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009066152-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | VAPA, SLC6A11, VAPB | MAPT 2307/4885KDM4E 3842/4885POLB 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.